摘要
目的分析血清MCP-1、HMGB-1水平与慢性肾衰竭(CRF)血液透析治疗患者预后情况的相关性。方法选择2019年4月至2020年4月在我院行血液透析治疗的210例CRF患者,于血液透析治疗前1 d检测血清MCP-1、HMGB-1水平,随访治疗6个月时患者的预后情况,分析血清MCP-1、HMGB-1水平与预后情况的相关性。结果210例CRF血液透析治疗患者预后不良74例(35.24%)。预后不良组的血清MCP-1、HMGB-1水平高于预后良好组(P<0.05)。多元Logistic回归分析显示,血清MCP-1、HMGB-1水平与CRF血液透析治疗患者的预后情况相关(OR>1,P<0.05)。结论血清MCP-1、HMGB-1水平与CRF血液透析治疗患者的预后密切相关,临床可根据上述指标水平对患者预后情况进行有效评估。
Objective To analyze the correlations of serum MCP-1 and HMGB-1 levels with the prognosis of chronic renal failure(CRF)patients treated with hemodialysis.Methods 210 CRF patients who underwent hemodialysis treatment in our hospital from April2019 to April 2020 were selected.Serum MCP-1 and HMGB-1 levels were detected 1 day before hemodialysis treatment,and the prognosis of the patients was followed up at 6 months of treatment.The correlations of serum MCP-1 and HMGB-1 levels with prognosis were analyzed.Results Of the 210 CRF patients treated with hemodialysis,74 cases(35.24%)had poor prognosis.The serum levels of MCP-1and HMGB-1 in the poor prognosis group were higher than those in the good prognosis group(P<0.05).Multivariate Logistic regression analysis showed that serum MCP-1 and HMGB-1 levels were associated with the prognosis of CRF patients treated with hemodialysis(OR>1,P<0.05).Conclusions The levels of serum MCP-1 and HMGB-1 are closely related to the prognosis of CRF patients treated with hemodialysis,and the prognosis of patients can be effectively evaluated according to the above index levels in clinic.
作者
李亚迪
钟莹莹
LI Yadi;ZHONG Yingying(Department of Blood Purification,the First Affiliated Hospital of He'nan University of Science and Technology,Luoyang 471000,China)
出处
《临床医学工程》
2022年第10期1475-1476,共2页
Clinical Medicine & Engineering
